In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months.

Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351

Back us on Patreon! www.patreon.com/plenarysession

April 2019

1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen

Plenary Session - inactive due to federal service